Potential Mediators of Efpeglenatide's Cardiovascular Benefit: An Exploratory Analysis of the AMPLITUDE-O Trial.

Diabetes Obes MetabJul 1, 2026 (epub)
Clinical ResearchCardiologyEndocrinologyOpen access

Daniel Raaschou-Oddershede, Christine R Schwarz, Tanya Kovalova et al.

✦ AI-curated · Sources linked

In 30 seconds

This exploratory analysis of the AMPLITUDE-O trial evaluated potential mediators of efpeglenatide's cardiovascular benefits in 4,076 individuals with Type 2 diabetes and cardiovascular or kidney disease. The study found that changes in LDL cholesterol and urinary albumin:creatinine ratio (UACR) accounted for 29.6% of the reduction in major cardiovascular events (MACE) associated with efpeglenatide.

Key findings

  • Efpeglenatide reduced major cardiovascular events by 27% compared to placebo.
  • Changes in HbA1c, LDL cholesterol, UACR, and amylase accounted for 14%, 11%, 16%, and 10% of the MACE reduction, respectively.
  • In multivariable analysis, LDL cholesterol and UACR together accounted for 29.6% of the mediation effect.

Why it matters

Understanding the mediators of cardiovascular benefits from diabetes treatments can help clinicians optimize patient management and improve outcomes in those with cardiovascular or kidney disease.

Source

PubMed · PMID 42387302Free full text on PubMed Central

Published in Diabetes Obes Metab. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.